UK markets close in 2 hours 18 minutes
  • FTSE 100

    7,469.14
    -37.97 (-0.51%)
     
  • FTSE 250

    20,285.82
    -12.18 (-0.06%)
     
  • AIM

    927.44
    +7.66 (+0.83%)
     
  • GBP/EUR

    1.1814
    -0.0043 (-0.37%)
     
  • GBP/USD

    1.2229
    +0.0011 (+0.09%)
     
  • BTC-GBP

    20,279.87
    +572.86 (+2.91%)
     
  • CMC Crypto 200

    584.88
    +53.66 (+10.10%)
     
  • S&P 500

    4,210.24
    +87.77 (+2.13%)
     
  • DOW

    33,309.51
    +535.11 (+1.63%)
     
  • CRUDE OIL

    93.42
    +1.49 (+1.62%)
     
  • GOLD FUTURES

    1,811.40
    -2.30 (-0.13%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    20,082.43
    +471.59 (+2.40%)
     
  • DAX

    13,739.90
    +38.97 (+0.28%)
     
  • CAC 40

    6,526.23
    +2.79 (+0.04%)
     

Brokers upbeat on Sanofi SA despite economic uncertainty

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The Sanofi SA (EPA:SAN) share price has risen by 3.38% over the past month and it’s currently trading at €100.1. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue.

According to the company’s analysts, there are certainly reasons to think it will continue to perform well in the year ahead. In terms of trading recommendations, Sanofi SA currently has:

  • 10 Buy recommendations

  • 6 Hold recommendations

  • 0 Sell recommendations

This suggests that analysts are generally positive about the outlook.

GET MORE DATA-DRIVEN INSIGHTS INTO EPA:SAN »

Researching beyond broker forecasts

At its current price of €100.1, shares in Sanofi SA are trading at a discount of -5.62% to its 52 week high price. The 1-year performance of the shares has been 15.4%.

While analyst forecasts can be a useful guide to what City 'experts' think about a stock's near term future, they can be unreliable. To get a better idea about the strengths and weaknesses of Sanofi SA it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Sanofi SA that you can find out about here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting